Portfolio update Feb 2024:
Post state election results in November 2023 I became bullish as political uncertainty came down drastically. However, in February screen was signaling softness. I raised my cash level as I watched earnings of the companies. Cash/bond now accounts for 56% of my net-worth and stocks 44%. I have shortlisted stocks where I want to ramp-up my position in the next few months.
I remain bullish on bonds as I think we are likely to see rate cut this year and that will have positive impact on bonds. Inclusion of India in various global bond indices will also percolate to private sector issuers. Some of the bonds in AA rating category continue to offer 10%+ yield. I expect my bond portfolio to provide 12% CAGR in 3 to 5 years due to rate cut over the next two years.
Equity portfolio:
I made a big decision of exiting Bajaj Finserv in this quarter. I was holding the stock for over 8 years and was anchor of my portfolio. I have become very sensitive of valuations I pay. So based on the combination of earnings and valuations I exited Shivalik, Permanent magnets, Clean Science, Tatva Chintan, Neogen Chemical, NAM-India, Divgi Torq and HFCL. As of today, I don’t have any R&D stocks in my portfolio.
As a result, concentration of my portfolio has increased. Now I own 16 stocks, top 5 account for 55% and top 10 – 87%.
Feb-24 | Jan-24 | Aug-23 | Nov-23 | |
---|---|---|---|---|
Total stocks | 16 | 21 | 23 | 22 |
Top 5 allocation | 55% | 46% | 42% | 38% |
Top 10 allocation | 87% | 74% | 71% | 71% |
New entrants are Syrma (re-entry), Restaurant Brands India, and Data Pattern.
I ramped up positions in Nuvama, Garware Hitech and Sandhar owing to great results.
Trim mode: Rategain is the only position which I intent to trim due to size. Results were fantastic. Mr. Bhanu Chopra has talked (in couple of interviews) about his aspiration to make the company a USD1 billion-dollar revenue company.
Tejas Network has been a big blow, down 23%, since I bought it. Results were also below my expectations. I hope company changes its trajectory from Q4 FY24. Margins I think will remain an issue. As it’s a Tata company I am fine to give it one or two more quarters.
PB Fintech and Rategain were the big winners in the last 3 month.
PB Fintech: Earnings momentum is strong. I am not sure of the outcome of tax survey but this company is at inflection. About 35% of incremental revenues is going to flow to EBITDA and bottomline. If take rates remain at same levels then by FY30 company should have topline of over 10K crore and PAT & EBITDA of over 3K crore. However, big risk is take rate (commission) suppression.
Anyone interested in PB Fintech kind of business then should read up on Goosehead Insurance in USA. This company is growing at over 30% rate from past several years despite being in low growth market. Their commission rate is 14%. Why I am mentioning this is because some of the investors think that commissions will be made 0%. If in USA, which is well penetrated market, commission is paid then it will not be taken away in an underpenetrated market like India. In fact, in March 2023 IRDAI removed the cap on commissions, earlier it used to be 20% and before that it was in 30% vicinity. I think PB fintech take rate is in 10-15% vicinity. Take rate reduction remains a risk and an investor should be able to react accordingly. Nevertheless, premium growth for PB fintech in my view shall remain in current trajectory of growth 30-40%.
Saregama continues to be below par. However, with industry change (paid subscription vs. ad supported revenue) I am expecting its earnings to bottom out in next couple of quarters and start showing 20% earnings growth from Q2 FY25. Finger crossed.
MapmyIndia: results were in line with my expectations. They won a big order of 400 crores with Hynduai and Kia. This order is almost 40%+ of order book they declared at the beginning of FY24. I am also excited for Q4 FY24 like the management.
Nuvama: Q3 FY24 earnings are very good. However, an investor should be careful of its high revenue in capital market segment. Capital market segment would be cyclical and any negative market sentiments may impact this segment’s revenue.
Please do not tail or copy my portfolio as you can see, I have a high churn and I can sell or buy any position at any time before informing/updating this group.
Disclaimer: I am not a financial advisor and nor a SEBI registered Analyst. The content shared here is only for learning purpose. All the names mentioned here are for example purpose. I may buy more, exit or partly sell the stock/bonds without any prior intimation.
Subscribe To Our Free Newsletter |